Tyrosine Kinase Inhibitors and Acute Pancreatitis

Raffaele Pezzilli; Roberto Corinaldesi; Antonio Maria Morselli-Labate

doi:10.6092/1590-8577/3836

Raffaele Pezzilli Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital and Alma Mater Studiorum - University of Bologna. Bologna, Italy
Roberto Corinaldesi Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital and Alma Mater Studiorum - University of Bologna. Bologna, Italy
Antonio Maria Morselli-Labate Department of Clinical Medicine, Sant’Orsola-Malpighi Hospital and Alma Mater Studiorum - University of Bologna. Bologna, Italy

DOI: https://doi.org/10.6092/1590-8577/3836

Keywords: 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3, 4-d)pyrimidine, Amylases, Clinical Trials, Controlled Clinical Trial, Drug Toxicity, Lipase, Pancreatitis

Downloads

Download data is not yet available.

References

Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007; 5:648-61. [PMID 17395548] (FULLTEXT: http://www.cghjournal.org/article/PIIS1542356506012018/fulltext)

Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid Cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010; Apr 14. [PMID 20392874] (FULLTEXT: http://jcem.endojournals.org/cgi/rapidpdf/jc.2009-1923v1)

Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000;60:2049-55. [PMID 10766197] (FULLTEXT: http://cancerres.aacrjournals.org/cgi/content/full/60/7/2049)

Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22:395-407. [PMID 19959090] (FULLTEXT: http://www.bprch.com/article/PIIS1521692609000668/fulltext)

Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-72. [PMID 15613696] (FULLTEXT: http://jco.ascopubs.org/cgi/content/full/23/5/965)

Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542-51. [PMID 16775235] (FULLTEXT: http://content.nejm.org/cgi/content/full/354/24/2542)

Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008; 61:515-24. [PMID 17505827] (FULLTEXT: http://www.springerlink.com/content/4155x3313w2r14q1/fulltext.html)

Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37:755-62. [PMID 17951335] (FULLTEXT: http://jjco.oxfordjournals.org/cgi/content/full/37/10/755)

Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99:159-65. [PMID 17953709] (FULLTEXT: http://www3.interscience.wiley.com/cgi-bin/fulltext/119415611/HTMLSTART)

le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111:1834-9. [PMID 18048643] (FULLTEXT: http://bloodjournal.hematologylibrary.org/cgi/content/full/111/4/1834)

Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14:5325-31. [PMID 18765523] (FULLTEXT: http://clincancerres.aacrjournals.org/content/14/17/5325.long)

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43:489-95. [PMID 19247201] (FULLTEXT: http://journals.lww.com/jcge/Abstract/2009/05000/Safety_and_Efficacy_of_Sorafenib_in_Patients_With.18.aspx)

Medioni J, Choueiri TK, Zinzindohoué F, Cho D, Fournier L, Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J Urol 2009; 181:2470-5. [PMID 19371877] (FULLTEXT: http://www.jurology.com/article/PIIS0022534709003486/fulltext)

Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int J Hematol 2009; 89:679-88. [PMID 19449194] (FULLTEXT: http://www.springerlink.com/content/01737475l25r5403/fulltext.html)

Zhou L, Meng F, Yin O, Wang J, Wang Y, Wei Y, et al. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther 2009; 31:1568-75. [PMID 19695406] (FULLTEXT: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-4X1HY54-8&_user=10&_coverDate=07%2F31%2F2009&_rdoc=1&_fmt=high&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=b29cf6df63d14151787c56bc4fde79de)

Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114:4933-8. [PMID 19822896] (FULLTEXT: http://bloodjournal.hematologylibrary.org/cgi/content/full/114/24/4933)

Chi KH, Liao CS, Chang CC, Ko HL, Tsang YW, Yang KC, Mehta MP. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010 Feb 2. [PMID 20133077] (FULLTEXT: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T7X-4Y9HP0J-D&_user=10&_coverDate=02%2F03%2F2010&_rdoc=1&_fmt=full&_orig=search&_cdi=5070&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=356602bbe7a8f138ea218695f4466dc8)

National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program (CTEP), 2006. (FULLTEXT: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf)

Bayer AG. Leverkusen, Germany. Nevaxar (sorafenib). Highlights of prescribing information. (FULLTEXT: http://www.univgraph.com/bayer/inserts/nexavar.pdf)

Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 2007; 100:909-11. [PMID 17902294] (FULLTEXT: http://journals.lww.com/smajournalonline/Fulltext/2007/09000/Acute_Pancreatitis_Associated_with_Sorafenib.15.aspx)

Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc 2007; 82:521. [PMID 17418082] (FULLTEXT: http://www.mayoclinicproceedings.com/content/82/4/521.1.long)

Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. JOP. J Pancreas (Online) 2010; 11:283-4. [PMID 20442531] (FULLTEXT: http://www.joplink.net/prev/201005/20.html)

Ueda T, Takeyama Y, Yasuda T, Matsumura N, Sawa H, Nakajima T, Kuroda Y. Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis. J Surg Res 2006; 134:223-30. [PMID 16488441] (FULLTEXT: http://www.journalofsurgicalresearch.com/article/PIIS0022480405012369/fulltext)

Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior RM, Deuel TF. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol 1989; 109:429-40. [PMID 2745556] (FULLTEXT: http://jcb.rupress.org/content/109/1/429.long)